Trials / Completed
CompletedNCT01605331
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life. Patients, however, do have to tolerate daily injections of GH (rhGH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sustained-release recombinant human GH (SR-rhGH) |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2012-05-24
- Last updated
- 2012-10-05
Source: ClinicalTrials.gov record NCT01605331. Inclusion in this directory is not an endorsement.